Published in Glia on March 28, 2011
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. J Clin Oncol (2015) 3.24
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell (2013) 2.98
Integrated morphologic analysis for the identification and characterization of disease subtypes. J Am Med Inform Assoc (2012) 2.68
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev (2011) 2.48
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol (2011) 2.27
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10
Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol (2012) 1.66
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med (2013) 1.59
Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell (2011) 1.49
PDGF and PDGF receptors in glioma. Ups J Med Sci (2012) 1.43
Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology (2012) 1.41
Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. Mol Syst Biol (2012) 1.36
CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J (2011) 1.32
Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun (2013) 1.26
Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology (2014) 1.23
Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. Neuro Oncol (2013) 1.20
Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res (2013) 1.20
Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol (2014) 1.17
Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One (2012) 1.11
Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro Oncol (2012) 1.09
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol (2012) 1.07
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07
miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A (2013) 1.06
A simplified approach for the molecular classification of glioblastomas. PLoS One (2012) 1.05
Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma. Neuro Oncol (2013) 1.05
TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dis (2014) 1.04
Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PLoS One (2012) 1.03
Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma. Cancer Res (2014) 0.99
From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity. Oncotarget (2015) 0.96
G-cimp status prediction of glioblastoma samples using mRNA expression data. PLoS One (2012) 0.96
The cancer stem cell subtype determines immune infiltration of glioblastoma. Stem Cells Dev (2012) 0.95
TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma. PLoS One (2011) 0.93
RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation. Cancer Res (2013) 0.92
The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implications. ScientificWorldJournal (2011) 0.91
Clinical implications of microRNAs in human glioblastoma. Front Oncol (2013) 0.88
Unique biology of gliomas: challenges and opportunities. Trends Neurosci (2012) 0.87
Glioma cell proliferation controlled by ERK activity-dependent surface expression of PDGFRA. PLoS One (2014) 0.86
Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget (2015) 0.86
TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells. Oncotarget (2016) 0.85
MicroRNAs in Human Malignant Gliomas. J Oncol (2012) 0.84
Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis. PLoS One (2013) 0.83
Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma. Oncotarget (2015) 0.83
Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients. PLoS One (2016) 0.82
Expression and functional heterogeneity of chemokine receptors CXCR4 and CXCR7 in primary patient-derived glioblastoma cells. PLoS One (2013) 0.82
Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression. J Proteomics (2014) 0.81
Dissecting cancer heterogeneity with a probabilistic genotype-phenotype model. Nucleic Acids Res (2013) 0.81
Clinical and molecular characteristics of congenital glioblastoma. Neuro Oncol (2012) 0.81
The genetic signatures of pediatric high-grade glioma: no longer a one-act play. Semin Radiat Oncol (2014) 0.80
NEDD4-1 regulates migration and invasion of glioma cells through CNrasGEF ubiquitination in vitro. PLoS One (2013) 0.80
Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. Oncotarget (2012) 0.80
Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. Neuroimage Clin (2016) 0.80
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol (2014) 0.80
Master regulators, regulatory networks, and pathways of glioblastoma subtypes. Cancer Inform (2014) 0.79
SSBP2 variants are associated with survival in glioblastoma patients. Clin Cancer Res (2012) 0.79
Targeting NF-κB in glioblastoma: A therapeutic approach. Sci Adv (2016) 0.79
Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis. PLoS One (2013) 0.78
RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop. Oncotarget (2015) 0.77
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma. Mol Oncol (2016) 0.77
Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma. Oncotarget (2016) 0.77
The complex role of transglutaminase 2 in glioblastoma proliferation. Neuro Oncol (2016) 0.77
Investigating the therapeutic role and molecular biology of curcumin as a treatment for glioblastoma. Ther Adv Med Oncol (2016) 0.76
Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells. Front Oncol (2016) 0.75
MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy. Top Magn Reson Imaging (2016) 0.75
Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases. Oncotarget (2016) 0.75
Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response. Immunotargets Ther (2014) 0.75
Double minute amplification of mutant PDGF receptor α in a mouse glioma model. Sci Rep (2015) 0.75
Differential response of patient-derived primary glioblastoma cells to environmental stiffness. Sci Rep (2016) 0.75
Clinical neuropathology practice guide 1-2013: molecular subtyping of glioblastoma: ready for clinical use? Clin Neuropathol (2013) 0.75
Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference. Oncotarget (2016) 0.75
Epithelial membrane protein 3 regulates TGF-β signaling activation in CD44-high glioblastoma. Oncotarget (2017) 0.75
The Role of miRNAs in Angiogenesis, Invasion and Metabolism and Their Therapeutic Implications in Gliomas. Cancers (Basel) (2017) 0.75
In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation. Cancer Res Front (2016) 0.75
APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death. Oncotarget (2017) 0.75
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell (2009) 4.94
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med (2012) 4.64
NFKBIA deletion in glioblastomas. N Engl J Med (2010) 3.96
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 3.34
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 3.34
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 1.82
Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proc Natl Acad Sci U S A (2007) 1.78
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell (2010) 1.68
The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg (2012) 1.67
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev (2013) 1.55
Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci U S A (2007) 1.54
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J (2011) 1.49
Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. Cancer Res (2013) 1.35
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A (2011) 1.21
Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res (2010) 1.21
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A (2013) 1.20
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol (2012) 1.17
Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma. Cancer Res (2012) 1.15
Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol (2012) 1.13
Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma. Cancer Res (2003) 1.12
Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol (2013) 1.11
Neurosurgery for brain tumors: update on recent technical advances. Curr Neurol Neurosci Rep (2011) 1.10
Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res (2013) 1.06
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res (2012) 1.02
PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol (2013) 1.00
Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res (2014) 0.98
Hypoxia and oxygenation induce a metabolic switch between pentose phosphate pathway and glycolysis in glioma stem-like cells. Acta Neuropathol (2013) 0.96
Isolated translocation of Wernicke's area to the right hemisphere in a 62-year-man with a temporo-parietal glioma. AJNR Am J Neuroradiol (2004) 0.95
TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma. PLoS One (2011) 0.93
MEF promotes stemness in the pathogenesis of gliomas. Cell Stem Cell (2012) 0.92
Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. Acta Neuropathol (2013) 0.90
Hippocampal dysfunction and behavioral deficit in the water maze in mice: an unresolved issue? Brain Res Bull (2002) 0.87
Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. Int J Cancer (2010) 0.83
Rescue of NGF-deficient mice I: transgenic expression of NGF in skin rescues mice lacking endogenous NGF. Brain Res Mol Brain Res (2004) 0.83
Discordance between functional magnetic resonance imaging during silent speech tasks and intraoperative speech arrest. J Neurosurg (2005) 0.82